
	Mr. David A. Arkowitz has been the Chief Financial Officer and Chief Operating Officer at Visterra, Inc., since December 2013. Mr. Arkowitz served as the Chief Financial Officer of Mascoma Corporation since June 14, 2011 and its Treasurer and Secretary since July 2011. He served as General Manager, Mascoma Grain Tech. Mr. Arkowitz served as the Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals, Inc. from April 5, 2007 to June 24, 2011 and also served as its Principal Accounting Officer, Executive Vice President and Treasurer until June 24, 2011. He was responsible for all finance, treasury, business development and investor relations functions at AMAG Pharmaceuticals. He has over two decades of finance leadership experience in the healthcare and life sciences industries. He served as Chief Financial Officer of Idenix Pharmaceuticals Inc. from December 2003 to March 30,2007 and served as its Treasurer from January 2004 to March 30, 2007 as well as its Principal Accounting Officer until March 30, 2007. Mr. Arkowitz was with Merck &amp; Co., Inc. for more than 13 years in a variety of financial leadership positions. He served as Vice president &amp; Controller, Merck U.S. Human Health from September 2002 to December 2003, where he provided financial leadership to the marketing and sales operations in the United States, Merck&#39;s largest market. In this role, Mr. Arkowitz was a key contributor to the spin-off of Medco Health, completed August 2003, and the establishment of a new distribution program for U.S. wholesalers. Mr. Arkowitz held positions of increasing responsibility with Merck, including Controller of the global research and development division from April 2000 to September 2002, Merck Research Laboratories and Vice President of Finance and Business Development for Merck&#39;s Canadian subsidiary from July 1997 to April 2000. Mr. Arkowitz held several senior finance and business development positions at Merck-Medco Managed Care, LLC, including Vice President of Financial Planning &amp; Analysis and Vice President of Business Development, and also served as Director of Financial Evaluation and Analysis, where he played a key role in Merck&#39;s acquisition of Medco Containment Services in 1993. He has been a Director of Spring Bank Pharmaceuticals, Inc. since January 28, 2014. He served as a Director of Impactrx, Inc. since August 2005. He served as Director of Aegerion Pharmaceuticals, Inc. since May 2007. Mr. Arkowitz holds a M.B.A. from Columbia University and a B.A. in Mathematics from Brandeis University.
